C. A. Raymond

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, F. Awan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

Derek A. West, Jeffrey A Jones, J. Byrd, 2008, Blood.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lisa L. Smith, J. Byrd, A. Johnson, 2010, Blood.

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2007 .

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, F. Awan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.